Amarin Plc recently held a conference call discussing their Q4 2024 earnings and business updates. They highlighted progress in global expansion, financial stability, regulatory advancements, and the value of their product VASCEPA in addressing cardiovascular risk.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay